isb 1442
mAbexperimentalBi-specific
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 27, 2022 (NCT05427812)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Leukocyte surface antigen CD47INHIBITOR
CD47 inhibitor
CD38 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05427812 | Phase 1/Phase 2 (Phase 2) | Sep 27, 2022 | Ichnos |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ichnos | For profit | 1 | 1 | 1 | 2022 |
1 organizations
Page 1 / 1